Abstract
Objectives Transcranial Low-Intensity Focused Ultrasound (LIFU) offers unique opportunities for precisely neuromodulating small and/or deep targets within the human brain, which may be useful for treating psychiatric and neurological disorders. This paper presents a novel ultrasound system that delivers focused ultrasound through the forehead to anterior brain targets and evaluates its safety and usability in a volunteer study.
Methods The ultrasound system and workflow are described, including neuronavigation, LIFU planning, and ultrasound delivery components. Its capabilities are analyzed through simulations and experiments to establish its safe steering range. A cohort of 20 healthy volunteers received a LIFU protocol aimed at the anterior medial prefrontal cortex (amPFC), using imaging and questionnaires to screen for adverse effects.
Results Simulations and hydrophone readings agreed with less than 5% error, and the safe steering range was found to encompass a 1.8cm x 2.5cm x 2cm volume. There were no adverse effects evident on qualitative assessments, nor any signs of damage in susceptibility-weighted imaging scans. All participants tolerated the treatment well, and the users found the interface effective as the system was capable of accurately targeting the amPFC in all participants. A post hoc analysis showed that “virtual fitting” could aid in steering the beams around subjects’ sinuses.
Conclusions The presented system was successfully used to safely deliver LIFU through the forehead to the amPFC in all volunteers, and was well-tolerated. With the capabilities validated here and positive results of the study, this technology appears well-suited to explore LIFU’s efficacy in clinical neuromodulation contexts.
Competing Interest Statement
This study was funded, in part, by an investigator-initiated grant to JJBA by Openwater. CRB, PJH, and SDK are full-time employees of Openwater.
Funding Statement
The study was funded by an investigator-initiated grant from Openwater.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board of the University of Arizona approved the experimental protocol. All participants signed an IRB-approved informed consent document before participation.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
